Interleukin-6 signaling pathway in targeted therapy for cancer

STATs and Gene Regulation

Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272

The STATs of cancer — new molecular targets come of age

Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130

Interleukin-6 in Biology and Medicine

Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389

What does Stat3 do?

Levy, D. E., & Lee, C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15650 · Cited by 810

Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial

Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., & Kishimoto, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20303 · Cited by 788

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779

What does Stat3 do?

Levy, D. E., & Lee, C.-K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215650 · Cited by 734

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666

The Jak-STAT pathway

Imada, K., & Leonard, W. J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00018-3 · Cited by 610

STAT proteins: From normal control of cellular events to tumorigenesis

Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., & Russo, A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10364 · Cited by 610

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566

Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway

Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Lai, K.-B., Lee, C.-N., & Hsieh, C.-Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206226 · Cited by 536

Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506

Interleukin-6: discovery of a pleiotropic cytokine.

Kishimoto, T. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1916 · Cited by 505

Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.

Chen, Z., Malhotra, P. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Smith, C. W., Enamorado, I. I., Yeh, N. T., Kroog, G. S., Rudy, S., et al. (1999) · PubMed · Cited by 486

Penetration of interleukin-6 across the murine blood-brain barrier

Banks, W. A., Kastin, A. J., & Gutierrez, E. G. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90933-4 · Cited by 485

STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells

Sherry, M. M., Reeves, A., Wu, J. K., & Cochran, B. H. (2009) · Stem Cells · doi:10.1002/stem.185 · Cited by 478

Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer

Salgado, R., Junius, S., Benoy, I., Van Dam, P., Vermeulen, P., Van Marck, E., Huget, P., & Dirix, L. Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10833 · Cited by 435

IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT3

Fielding, C. A., McLoughlin, R. M., McLeod, L., Colmont, C. S., Najdovska, M., Grail, D., Ernst, M., Jones, S. A., Topley, N., & Jenkins, B. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2189 · Cited by 408

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390

Interleukin-6 in bone metastasis and cancer progression

Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379

Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics

Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370

Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?

Grivennikov, S., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.020 · Cited by 368

Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine

Nilsson, M. B., Langley, R. R., & Fidler, I. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0623 · Cited by 349

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

Mihara, M., Kasutani, K., Okazaki, M., Nakamura, A., Kawai, S., Sugimoto, M., Matsumoto, Y., & Ohsugi, Y. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.05.010 · Cited by 328

Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.

Zhang, G.-J., & Adachi, I. (1999) · PubMed · Cited by 306

Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer

Scheller, J., Ohnesorge, N., & Rose‐John, S. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01750.x · Cited by 297

STAT‐mediated EGFR signaling in cancer

Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21475 · Cited by 295

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

Qiu, Y., Ravi, L., & Kung, H.-J. (1998) · Nature · doi:10.1038/30012 · Cited by 280

Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.

Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 280

Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.

Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 274

Interleukin-6 regulation of prostate cancer cell growth.

Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269

IL-6 involvement in epithelial cancers

Schafer, Z. T., & Brugge, J. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34237 · Cited by 269

Epstein – Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors

Eliopoulos, A. G., Stack, M., Dawson, C. W., Kaye, K. M., Hodgkin, L., Sihota, S., Rowe, M., & Young, L. S. (1997) · Oncogene · doi:10.1038/sj.onc.1201258 · Cited by 258

Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer

Duan, Z., Foster, R., Bell, D. A., Mahoney, J., Wolak, K., Vaidya, A., Hampel, C., Lee, H., & Seiden, M. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0861 · Cited by 247

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2377 · Cited by 243

Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer

Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., & Martínez-Maza, O. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90582-c · Cited by 238

A review of the cytokine network in multiple myeloma: Diagnostic, prognostic, and therapeutic implications

Lauta, V. M. (2003) · Cancer · doi:10.1002/cncr.11072 · Cited by 232

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

Dorff, T. B., Goldman, B., Pinski, J. K., Mack, P. C., Lara, P. N., Van Veldhuizen, P. J., Quinn, D. I., Vogelzang, N. J., Thompson, I. M., & Hussain, M. H. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 212

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

Wang, Y., Niu, X. L., Qu, Y., Wu, J., Zhu, Y. Q., Sun, W. J., & Li, L. Z. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.019 · Cited by 210

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

William, A. D., Lee, A. C.-H., Blanchard, S., Poulsen, A., Teo, E. L., Nagaraj, H., Tan, E., Chen, D., Williams, M., Sun, E. T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200326p · Cited by 201

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

Scambia, G., Testa, U., Benedetti Panici, P., Foti, E., Martucci, R., Gadducci, A., Perillo, A., Facchini, V, Peschle, C., & Mancuso, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.71 · Cited by 198

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., Qi, M., Bandekar, R., Vermeulen, J. T., Cornfeld, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 197

Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer

Belluco, C., Nitti, D., Frantz, M., Toppan, P., Basso, D., Plebani, M., Lise, M., & Jessup, J. M. (2000) · Annals of Surgical Oncology · doi:10.1007/s10434-000-0133-7 · Cited by 196

Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

Penson, R. T., Kronish, K., Duan, Z., Feller, A. J., Stark, P., Cook, S. E., Duska, L. R., Fuller, A. F., Goodman, A. K., Nikrui, N., et al. (2000) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2000.00003.x · Cited by 192

Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma

Huang, S.-P., Wu, M.-S., Shun, C.-T., Wang, H.-P., Lin, M.-T., Kuo, M.-L., & Lin, J.-T. (2004) · Journal of Biomedical Science · doi:10.1007/bf02256101 · Cited by 190

Constitutive Activation of Stat 3 Oncogene Product in Human Ovarian Carcinoma Cells

Huang, M., Page, C., Reynolds, R. K., & Lin, J. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5931 · Cited by 189

Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.

Badache, A., & Hynes, N. E. (2001) · PubMed · Cited by 189

Molecular and cellular biology of interleukin-6 and its receptor

Keller, E. T. (1996) · Frontiers in Bioscience · doi:10.2741/a136 · Cited by 182

Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6—From the Groupe Français d'Immunothérapie

Negrier, S., Perol, D., Menetrier-Caux, C., Escudier, B., Pallardy, M., Ravaud, A., Douillard, J.-Y., Chevreau, C., Lasset, C., & Blay, J.-Y. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.121 · Cited by 176

Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer

Plante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1882::aid-cncr2820730718>3.0.co;2-r · Cited by 173

Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

Borsellino, N., Belldegrun, A. S., & Bonavida, B. (1995) · PubMed · Cited by 171

The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480

George, D. J., Halabi, S., Shepard, T. F., Sanford, B., Vogelzang, N. J., Small, E. J., & Kantoff, P. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1560 · Cited by 168

Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways

Leu, C.-M., Wong, F.-H., Chang, C., Huang, S.-F., & Hu, C.-P. (2003) · Oncogene · doi:10.1038/sj.onc.1207084 · Cited by 168

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166

Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.

Duan, Z., Feller, A. J., Penson, R. T., Chabner, B. A., & Seiden, M. V. (1999) · PubMed · Cited by 165

Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma

Shinriki, S., Jono, H., Ota, K., Ueda, M., Kudo, M., Ota, T., Oike, Y., Endo, M., Ibusuki, M., Hiraki, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0287 · Cited by 163

Upregulation of DNA Methyltransferase–Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6

Foran, E., Garrity-Park, M. M., Mureau, C., Newell, J., Smyrk, T. C., Limburg, P. J., & Egan, L. J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0496 · Cited by 160

Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor

Ashizawa, T., Okada, R., Suzuki, Y., Takagi, M., Yamazaki, T., Sumi, T., Aoki, T., Ohnuma, S., & Aoki, T. (2005) · Gastric Cancer · doi:10.1007/s10120-005-0315-x · Cited by 158

Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications

Nikiteas, N. I. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i11.1639 · Cited by 156

IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR

Rojas, A., Liu, G., Coleman, I., Nelson, P. S., Zhang, M., Dash, R., Fisher, P. B., Plymate, S. R., & Wu, J. D. (2011) · Oncogene · doi:10.1038/onc.2010.605 · Cited by 155

Elevated Serum Interleukin-6 Levels in Patients with Pancreatic Cancer

Okada, S., Okusaka, T., Ishii, H., Kyogoku, A., Yoshimori, M., Kajimura, N., Yamaguchi, K., & Kakizoe, T. (1998) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/28.1.12 · Cited by 153

Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice

Wallner, L. P., Dai, J., Escara-Wilke, J. F., Zhang, J., Yao, Z., Lü, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 148

Inflammation, HCC and sex: IL-6 in the centre of the triangle

Prìeto, J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.007 · Cited by 140

Serum interleukin-6 levels reflect disease status of gastric cancer.

Wu, C.-H., Wang, S. R., Chao, M. F., Wu, T., Lui, W. Y., Peng, F., & W, C. (1996) · PubMed · Cited by 139

Interleukin-6 Induced Basic Fibroblast Growth Factor-Dependent Angiogenesis in Basal Cell Carcinoma Cell Line via JAK/STAT3 and PI3-Kinase/Akt Pathways

Jee, S., Chu, C., Chiu, H.-C., Huang, Y., Tsai, W.-L., Liao, Y., & Kuo, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23497.x · Cited by 139

HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis

Hartman, Z. C., Yang, X.-Y., Glass, O., Lei, G., Osada, T., Dave, S. S., Morse, M. A., Clay, T. M., & Lyerly, H. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0308 · Cited by 137

The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis

Rosen, D. G., Mercado‐Uribe, I., Yang, G. S., Bast, R. C., Amin, H. M., Lai, R. L., & Liu, J. (2006) · Cancer · doi:10.1002/cncr.22293 · Cited by 133

IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma

Cozen, W., Gill, P. S., Ingles, S. A., Masood, R., nez-Maza, O. M. I., Cockburn, M., Gauderman, W. J., Pike, M. C., Bernstein, L., Nathwani, B. N., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2860 · Cited by 131

Rational design of a receptor super‐antagonist of human interleukin‐6.

Savino, R., Ciapponi, L., Lahm, A., Demartis, A., Cabibbo, A., Toniatti, C., Delmastro, P., Altamura, S., & Ciliberto, G. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06931.x · Cited by 127

Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.

Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y., & Yoshida, O. (1995) · PubMed · Cited by 127

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

Pardanani, A. D., Vannucchi, A. M., Passamonti, F., Cervantes, F., Barbui, T., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.269 · Cited by 125

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

Santer, F. R., Malinowska, K., Čulig, Z., & Cavarretta, I. T. R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0200 · Cited by 120

A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

Fulciniti, M., Hideshima, T., Vermot‐Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E., Wang, W., PRABHALA, R. H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1483 · Cited by 119

Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., Corringham, R. E., Zaki, M. H., Nemeth, J. A., & Orlowski, R. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1293 · Cited by 118

Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms

Émilie, D., Wijdenes, J., Gisselbrecht, C., Jarrousse, B., Billaud, É., Blay, J., Gabarre, J., Gaillard, J., Brochier, J., & Raphaël, M. (1994) · Blood · doi:10.1182/blood.v84.8.2472.2472 · Cited by 118

The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 116

Interleukin-6 as a Therapeutic Target in Candidate Inflammatory Diseases

Nishimoto, N. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.313 · Cited by 116

Clinical Significance of Serum Cytokine Measurements in Untreated Colorectal Cancer Patients: Soluble Tumor Necrosis Factor Receptor Type I – An Independent Prognostic Factor

Kaminska, J. A., Nowacki, M. P., Kowalska, M. M., Rysińska, A., Chwaliński, M., Fuksiewicz, M., Michalski, W., & Chechlińska, M. (2005) · Tumor Biology · doi:10.1159/000086951 · Cited by 107

Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer

Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106

Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

Mesa, R. A. (2010) · PubMed · Cited by 105

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

Cavarretta, I. T. R., Neuwirt, H., Untergasser, G., Moser, P. L., Zaki, M. H., Steiner, H., Rumpold, H. F., Fuchs, D., Hobisch, A., Nemeth, J. A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210097 · Cited by 105

Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

Puchalski, T. A., Prabhakar, U., Jiao, Q., Berns, B., & Davis, H. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2581 · Cited by 105

Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: The role for KDR and MMP-9

Yao, J. S., Zhai, W., Young, W. L., & Yang, G. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.100 · Cited by 104

Combined targeting of interleukin‐6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness

Saidi, A., Hagedorn, M., Allain, N., Verpelli, C., Sala, C., Bello, L., Bikfalvi, A., & Javerzat, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24380 · Cited by 101

Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer

Songür, N., Kuru, B., Kalkan, F., Özdilekcan, Ç., Çakmak, H., & Hızel, N. (2004) · Tumori Journal · doi:10.1177/030089160409000207 · Cited by 96

INTERLEUKIN-6 AND THE NETWORK OF SEVERAL CYTOKINES IN MULTIPLE MYELOMA: AN OVERVIEW OF CLINICAL AND EXPERIMENTAL DATA

Lauta, V. M. (2001) · Cytokine · doi:10.1006/cyto.2001.0982 · Cited by 90

A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myeloma

Moreau, P., Harousseau, J., Wijdenes, J., Morineau, N., Milpied, N. J., & Bataille, R. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02093.x · Cited by 89

Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death

Voorhees, P. M., Chen, Q., Small, G. W., Kuhn, D. J., Hunsucker, S. A., Nemeth, J. A., & Orlowski, R. Z. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07647.x · Cited by 89

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

Mihara, M., Nishimoto, N., & Ohsugi, Y. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.5.683 · Cited by 88

Interleukin‐6 is responsible for drug resistance and anti‐apoptotic effects in prostatic cancer cells

Pu, Y., Hour, T., Chuang, S., Cheng, A., Lai, M., & Kuo, M. (2004) · The Prostate · doi:10.1002/pros.20057 · Cited by 84

Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation

Leslie, K., Gao, S. P., Berishaj, M., Podsypanina, K., Ho, H. H., Ivashkiv, L. B., & Bromberg, J. (2010) · Breast Cancer Research · doi:10.1186/bcr2725 · Cited by 82

IL‐6, its receptors and its relationship with bcl‐2 and bax proteins in infiltrating and in situ human breast carcinoma

García‐Tuñón, I., Ricote, M., Ruiz, A., Fraile, B., Paniagua, R., & Royuela, M. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02178.x · Cited by 76

Interleukin-6 level in patients with colorectal cancer

Esfandi, F., Ghobadloo, S. M., & Basati, G. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.003 · Cited by 76

IL-6–Induced Stimulation of c-Myc Translation in Multiple Myeloma Cells Is Mediated by Myc Internal Ribosome Entry Site Function and the RNA-Binding Protein, hnRNP A1

Shi, Y., Frost, P., Hoang, B. Q., Benavides, A., Sharma, S., Gera, J., & Lichtenstein, A. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1066 · Cited by 75

IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: Regulation by SOCS3

Sun, R., Jaruga, B., Kulkarni, S., Sun, H., & Gao, B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.171 · Cited by 73

OVEREXPRESSION OF IL-6 BUT NOT IL-8 INCREASES PACLITAXEL RESISTANCE OF U-2OS HUMAN OSTEOSARCOMA CELLS

Duan, Z., Lamendola, D. E., Penson, R. T., Kronish, K., & Seiden, M. V. (2002) · Cytokine · doi:10.1006/cyto.2001.1008 · Cited by 72

High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer

Bellone, S., Watts, K. E., Canè, S., Palmieri, M., Cannon, M. J., Burnett, A., Roman, J. J., Pecorelli, S. L., & Santin, A. D. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.03.016 · Cited by 71

Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells

Wang, Y. D., Vos, J. D., Jourdan, M., Couderc, G., Lu, Z., Rossi, J., & Klein, B. (2002) · Oncogene · doi:10.1038/sj.onc.1205355 · Cited by 66

An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells

Grant, S. L., Hammacher, A., Douglas, A. M., Goss, G. A., Mansfield, R., Heath, J. K., & Begley, C. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205100 · Cited by 64

Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

Hsu, J.-H., Shi, Y., Frost, P., Yan, H., Hoang, B. Q., Sharma, S., Gera, J., & Lichtenstein, A. K. (2004) · Oncogene · doi:10.1038/sj.onc.1207459 · Cited by 62

IL-6 and MYC collaborate in plasma cell tumor formation in mice

Rutsch, S., Neppalli, V. T., Shin, D., Dubois, W., Morse, H. C., Goldschmidt, H., & Janz, S. (2009) · Blood · doi:10.1182/blood-2009-08-237941 · Cited by 61

Cutaneous castleman's disease responds to anti–interleukin-6 treatment

Ahmed, B., Tschen, J. A., Cohen, P. R., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0256 · Cited by 56

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders

Dawson, M. A., Curry, J. E., Barber, K., Beer, P. A., Graham, B. L., Lyons, J. F., Richardson, C. J., Scott, M. A., Smyth, T., Squires, M. S., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08175.x · Cited by 55

c‐Met signaling promotes IL‐6‐induced myeloma cell proliferation

Hov, H., Tian, E., Holien, T., Holt, R. U., Våtsveen, T. K., Fagerli, U., Waage, A., Børset, M., & Sundan, A. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01212.x · Cited by 54

Gateways to clinical trials

Tomillero, A., & Moral, M. A. (2010) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2010.32.9.1563109 · Cited by 54

Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: Relevance for tumour progression

Brozek, W., Bises, G., Girsch, T., Cross, H. S., Kaiser, H. E., & Peterlik, M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.014 · Cited by 51

Serum level of interleukin‐16 in multiple myeloma patients and its relationship to disease activity

Alexandrakis, M. G., Passam, F. H., Kyriakou, D., Christophoridou, A. V., Perisinakis, K., Hatzivasili, A., Foudoulakis, A., & Castanas, E. (2004) · American Journal of Hematology · doi:10.1002/ajh.10444 · Cited by 46

Interleukin-6 and C-Reactive Protein in Metastatic Renal Cell Carcinoma

Altundağ, Ö., Altundağ, K., & Gündüz, E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.155 · Cited by 45

Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells.

Suchi, K., Fujiwara, H., Okamura, S., Okamura, H., Umehara, S., Todo, M., Furutani, A., 米田, 政., Shiozaki, A., Kubota, T., et al. (2011) · PubMed · Cited by 42

The Blockade of IL-6 Signaling in Rational Drug Design

Adachi, Y., Yoshio‐Hoshino, N., & Nishimoto, N. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784246072 · Cited by 40

Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6.

Okamoto, M., Kawamata, H., Kawai, K., & Oyasu, R. (1995) · PubMed · Cited by 40

Targeted therapies in multiple myeloma

Kastritis, E., Charidimou, A., Varkaris, A. S., & Dimopoulos, M. A. (2009) · Targeted Oncology · doi:10.1007/s11523-008-0102-9 · Cited by 36

Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals

Ishikawa, H., Tsuyama, N., Liu, S., Abroun, S., Li, F., Otsuyama, K., Xu, Z., Ma, Z., Maki, Y., Iqbal, M. S., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208782 · Cited by 33

The Role of Cytokines in the Pathogenesis and Management of Aids-Related Lymphomas

Fassone, L., Gaïdano, G., Ariatti, C., Vivenza, D., Capello, D., Gloghini, A., Cilia, A. M., Buonaiuto, D., Rossi, D., Pastore, C., et al. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009059266 · Cited by 20

[Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma].

Zakrzewska, I., & Poznański, J. (2001) · PubMed · Cited by 12

Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress

Tohme, S., Yazdani, H. O., Al-Khafaji, A. B., Chidi, A. P., Loughran, P., Mowen, K., Wang, Y., Simmons, R. L., Huang, H., & Tsung, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1591 · Cited by 694

The Role of Cytokines in Breast Cancer Development and Progression

Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I., & Morales-Montor, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0026 · Cited by 490

Cancer-associated adipocytes: key players in breast cancer progression

Wu, Q., Li, B., Li, Z., Li, J., Sun, S., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0778-6 · Cited by 462

Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line

Ortiz-Montero, P., Londoño-Vallejo, A., & Vernot, J.-P. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0172-3 · Cited by 428

The Biology and Medical Implications of Interleukin-6

Tanaka, T., & Kishimoto, T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0022 · Cited by 375